Synthego, a leading CRISPR solutions provider, announced that it has completed the sale of nearly all its assets to funds managed by Perceptive Advisors, a prominent life sciences investment firm. The deal was finalized on July 18, 2025.
Under new ownership by Perceptive, Synthego will continue to operate as usual, focusing on delivering high-quality CRISPR products and services worldwide. Its leadership and staff will remain unchanged, ensuring smooth daily operations and customer support. The Synthego brand will stay the same, with the website and email domain remaining synthego.com.
This acquisition strengthens Synthego’s mission to advance scientific discovery through cutting-edge genomic engineering. The company will continue to produce its top-grade guide RNA in Redwood City, California, supporting the global development of CRISPR-based therapies.
In May, Synthego launched a GMP version of SpCas9, and in July, it expanded its gene editing offerings with new enzymes, eSpOT-ON and Accubase, along with related guide RNA products.
KEY QUOTES:
“We are thrilled to officially complete this transaction and embark on a new chapter with Perceptive Advisors. This partnership strengthens our financial position and provides us with enhanced resources to accelerate innovation and expand our product portfolio in the months ahead. We remain fully committed to supporting our clients in their groundbreaking research and therapeutic development efforts.”
Craig Christianson, CEO of Synthego
“We’re incredibly excited about working closely with Perceptive Advisors. Our customers’ successes inspire us daily, and this partnership ensures we can both expand our offerings and accelerate our mission to deliver the most advanced and reliable CRISPR solutions for their critical work.”
Jason Miller, Chief Commercial Officer of Synthego
